Latest News - TearScience

Thursday, November 09, 2017

Johnson & Johnson Vision Announces TearScience LipiScan and LipiFlow Now Available in More Than 800 Eye Care Practices

TearScience, now a part of Johnson & Johnson Vision, announced at the American Academy of Ophthalmology (AAO) 2017 Meeting that its LipiScan and LipiFlow technologies are now available in more tha…

Read the full story

Wednesday, September 06, 2017

Johnson & Johnson Vision Completes Acquisition of TearScience

Johnson & Johnson Vision announced that it has completed its acquisition of TearScience. Terms of the deal were not disclosed. The move expands Johnson & Johnson's eye health portfolio and…

Read the full story

Friday, August 04, 2017

Johnson & Johnson Vision Announces Agreement to Acquire TearScience

Johnson & Johnson Vision announced a definitive agreement to acquire TearScience, a privately held medical device manufacturer dedicated to evaluating meibomian gland health and treating meibomian…

Read the full story

Saturday, May 06, 2017

CheckedUp and TearScience Team Up to Impact Dry Eye Patient Education

CheckedUp announced a nationwide partnership with TearScience, the maker of Lipiflow, to introduce the CheckedUp Engagement Platform to TearScience customers. The CheckedUp platform engages patients a…

Read the full story

Thursday, May 04, 2017

TearScience Introduces LipiFlow Activator II

TearScience announced the release of the LipiFlow Activator II treatment disposable. The newly released disposable maintains the same level of quality and efficacy as the original Activator. LipiFl…

Read the full story

Tuesday, May 02, 2017

TearScience: LipiFlow Treatment Benefits Patients with MGD and Presumed Sjögren’s Syndrome

TearScience released the results of a physician-sponsored study titled “Meibomian gland dysfunction patients with novel Sjögren’s syndrome biomarkers benefit significantly from a sing…

Read the full story

Monday, January 16, 2017

TearScience Appoints Clarion Medical to Distribute Meibomian Gland Dysfunction Product in Canada

TearScience announced that Clarion Medical has been appointed Canadian distributor, providing TearScience’s technologies to all Canadian provinces except Quebec, where Oeilsec continues successf…

Read the full story

Tuesday, August 23, 2016

A Single LipiFlow Treatment Demonstrates Sustained Improvement in Gland Function and Symptoms in Patients with MGD and Dry Eye

TearScience announced the publication of a seminal prospective, multicenter clinical trial showing that a single LipiFlow treatment can deliver sustained mean improvement in meibomian gland function a…

Read the full story

Monday, August 08, 2016

TearScience Names Edward J. Holland, MD, to Board of Directors

TearScience announced the addition of Edward J. Holland, MD, to its board of directors, according to a company news release. Dr. Holland was awarded the Life Achievement Honor Award at the 2012 Americ…

Read the full story

Thursday, May 05, 2016

TearScience Introduces LipiScan for Rapid High-Definition Meibomian Imaging

TearScience announced the release of LipiScan, the first dedicated high-definition gland imager that allows eye care professionals to assess meibomian gland structure during routine workups in a pract…

Read the full story

Thursday, April 14, 2016

TearScience Launches to Educate Patients About Meibomian Gland Dysfunction

TearScience has launched a new consumer education portal, The website is an additional resource for eye care practices to educate about meibomian gland dysfunction (MGD) -- the leadi…

Read the full story

Tuesday, January 12, 2016

TearScience North American Sales Grew 35% in 2015

TearScience has announced 35% sales growth year over year. The number of practices purchasing the company’s diagnostic and treatment for meibomian gland disease (MGD) and dry eye doubled in 2015…

Read the full story

Wednesday, October 28, 2015

TearScience Announces New Pricing For Core LipiFlow Technology Used For Treatment Of Dry Eye From Meibomian Gland Disease

TearScience has announced a 50% price cut, effective immediately, on the single-use activators used with the LipiFlow treatment platform for meibomian gland disease (MGD). The move is one component of…

Read the full story

Tuesday, September 08, 2015

TearScience: Strong Efficacy of LipiFlow Demonstrated Across 31 Peer-Reviewed Reports

TearScience announced the results of a major review demonstrating that a single LipiFlow procedure can significantly improve meibomian gland function and relieve symptoms associated with meibomian gla…

Read the full story

Monday, February 23, 2015

Tearscience Names Joseph Boorady CEO

Tearscience announced that Joseph Boorady, OD, will take the helm as president and chief executive officer. Dr. Boorady joins TearScience from Carl Zeiss Meditec, where he was senior vice presid…

Read the full story